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The phenomenon of tumour associated hypoglycaemia is
now well established as a form of non-insulin dependent
fasting hypoglycaemia generally coincident with the presence
of large mesenchymal tumours (Kahn, 1980). The effect is
most commonly seen in adults between the ages of40 and 70,
and most frequently with tumours such as fibrosarcoma and
rhabdomyosarcoma, although it has been reported with hep-
atoma and adrenal cortical carcinoma. A plethora of mech-
anisms have been suggested to explain how tumours of this
nature influence glucose homeostasis. At the most simple
level, the observation that hypoglycaemia usually occurs
when the tumour has reached a very large size, suggests that
the high rate of glycolytic metabolism of tumour tissue might
lead to a critical depletion of circulating glucose. However,
no evidence has been presented as to the rate of glucose
uptake by such tumours. A more persuasive explanation is
that the tumour is producing small diffusible molecules, such
as peptides, which mimic the effect of insulin. Obvious can-
didates for this role are the insulin like growth factors. The
IGFs are single chain polypeptides, evolutionarily related to
insulin, which exert a wide range of pleiotropic effects on
their target cells. At high concentrations they share the ana-
bolic effects of insulin, via the insulin receptor, but at normal
physiological concentrations IGFI and II act via their own
receptors to promote cell growth multiplication and
differentiation in different systems (Hill et al., 1987). Elevated
levels of IGF mRNA have been found in tumour types often
associated with hypoglycaemia, e.g. liposarcoma and leio-
myosarcoma (Tricoli et al., 1986; Hoppener et al., 1988), and
an elevated concentration of IGF has been reported in pa-
tients with hypoglycaemia (Gordon et al., 1981).
A recent report claimed that elevated levels of insulin-like
growth factor II were responsible for hypoglycaemia in pa-
tients with leiomyosarcoma, and suggested that such aberrent
expression of IGFII might contribute to tumour formation.
However, several groups have been unable to show elevation
ofeither IGF protein in patients' serum (Widmer et al., 1983;
Merimee, 1986, Haselbacher et al., 1987). We report here a
study of a female patient with a para-ovarian sarcoma
associated with spontaneous hypoglycaemia. Levels of tu-
mour IGFII mRNA were elevated around 30-fold with res-
pect to normal tissue or human fibroblasts, whereas levels of
IGFI or insulin mRNAs were low and undetectable respec-
tively. However, assay of serum showed a suppression of
IGF activity and tumour cyst fluid was found to contain
little IGF.
A 57-year-old woman presented with attacks of confusion
and drowsiness in the morning relieved by food. Fasting
hypoglycaemia, with plasma glucose 1.5-2.1 mmol l-' was
accompanied by low plasma insulin, 0.6 mUI', C-peptide
0.01 nmoll' (normal range: insulin, 3-12 mUI1'; C-pep-
tide, 0.2-0.8 nmol 1'), which excluded an insulinoma. A CT
scan showed a large left iliac fossa mass and at operation a
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large mucinous tumour with cysts was excised except for
infiltration of the sigmoid colon and small bowel. Post-
operatively she was normoglycaemic. Histology showed a
malignant sarcoma. Plasma samples were taken for an IGF
assay after an overnight fast, before the operation and after
recovery from the operation. At operation tumour cyst fluid
was aspirated for IGF assay. Fragments of tumour were put
into primary tissue culture, and the supernatent assayed for
IGFs.
RNA was prepared from fresh tumour tissue as described
in (Hyldahl et al., 1986), and Northern blot and SI nuclease
protection assays as in (Schofield & Tate, 1987). The probe
used for the Northern analysis was the Hinfl-Pstl fragment
of pHepS (Schofield & Tate, 1987), containing only coding
region sequence. The S1 analysis probes are described in the
above reference, and consisted of the AvaII-PvuII fragment
of pHIGFII labelled at the AvaII site in exon E2 of the
IGFII gene using T4 polynucleotide kinase in the presence of
T-32P ATP. The insulin probe was the kind gift of Dr
Graham Bell (Bell et al., 1979), and the IGFI probe of Prof.
J. Scott (Bell et al., 1984). Radioimmunoassay of IGFI and
II was carried out according to Zapf et al. (1981).
Figure 1 shows the results of probing 10gg of total RNA
from the sarcoma with probes for both the IGFs and insulin
mRNAs. The only signal visible from the tumour, even after
long exposure, was for IGFII, with two messenger RNAs of
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Figure I Northern blot analysis of sarcoma RNA 10jug of total
RNA from the tumour were electrophoresed on a 0.8% agarose
denaturing gel, blotted to nitrocellulose and probed with IGF II
coding sequences as described in Materials and methods. Markers
were an RNA ladder purchased from BRL Ltd.
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6.0 and 4.8 kb, which qualitatively resemble the RNA sizes
from extrahepatic transcription during adult and fetal life.
The quantity of transcripts, however, is much more similar to
that seen in fetal tissue, representing a 30-fold increase in
transcript levels as compared to normal fibroblasts, and
higher than any normal adult tissue so far examined
(Schofield & Tate, 1987; Scott et al., 1985).
S1 nuclease protection analysis was carried out to deter-
mine which of the three known IGF promoters was used in
this tumour. The presence of a protected fragment of 214 bp
in Figure 2 demonstrates that the major promoter is El(l),
high levels of expression from which are characteristic of
fetal tissues. Further analysis (not shown), using a single
stranded probe crossing the position of alternative splicing at
Ser 26 which inserts a tetrapeptide into the sequence, suggests
that the variant IGFII (Jansen et al., 1985) is beneath the
levels of detection. The group of bands visible at 143bp in
the long exposure shown in Figure 2 indicate a small propor-
tion of alternative 5' ends derived from the 'hepatic' pro-
moter of IGFII. A small proportion of these transcripts are
frequently seen in non-hepatic tissues.
Results of IGF radioimmunoassay are shown in Table I.
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Figure 2 S1 nuclease protection analysis of sarcoma and other
RNA samples. 10 1tg of total RNA was hybridised to end labelled
probe, as described in Materials and methods, digested with S1
nuclease and electrophoresed along with end labelled 123bp lad-
der of DNA fragments.
Table 1 Radioimmunoassay of IGFs
Sample IGFI (ngml-') IGFII (ngml-')
Plasma preop. <10 335
Plasma postop. 140 738
Tumour cyst fluid 16 137
Tissue culture supernatant 4 <10
Plasma normal range 120-300 500-900
Preoperative plasma level of IGFI was dramatically de-
creased and the IGFII level was subnormal. This suppression
has been noted before in patients suffering from tumour
hypoglycaemia (Widmer et al., 1983; Merimee, 1986). Post-
operatively, both levels become normal. Neither the tumour
cyst fluid or the primary tissue culture supernatant had high
levels of IGFI or II.
This is the first report of tumour associated hypoglycaemia
in which both IGF mRNA and plasma and tumour cyst fluid
IGF concentrations have been measured in the same patient.
We have identified a paradoxical situation in which IGFII
mRNA is substantially elevated in the tumour, but peptide
levels are suppressed in both tumour cyst fluid and serum.
This raises questions about the post transcriptional expres-
sion of the IGFII gene. Haselbacher et al. (1987) have pre-
viously reported increased mRNA but not IGFII peptides in
a series of Wilm's tumours, and a careful systematic study of
the ratio of peptide to mRNA for both IGFI and II by Han
et al. (1988) supports the notion that at least some of the
mRNAs derived from the IGFII transcription unit are trans-
lated poorly if at all. Alternative explanations might be that
all the IGFII produced by the tumour was either not secreted
or rapidly internalised by tumour cell receptors and never
exchanged into bulk medium. This hypothesis would be very
difficult to test, but strongly suggests that in cases where it is
proposed that autocrine growth is induced by inappropriate
tumour growth factor production, all measurements of
mRNA for the factor should be accompanied by assay of
protein production.
A recent report (Daughaday et al., 1988) suggested that
tumour hypoglycaemia associated with a case of leiomyosar-
coma was due to an increased proportion of a high molecular
weight form of IGFII, present both in the circulation and in
the tumour. Preoperative levels of acid/ethanol extractable
IGF were low/normal in this patient, and the large molecular
weight form of IGFII may represent a partially processed or
unprocessed form of the molecule. In the case studied by us,
lack of substantial quantity of total IGFII in tumour cyst
fluid suggests that the tumour was not acting as a source of
IGFII, and indicates that the hypoglycaemia was not due to
circulating IGFII of tumour origin. However, we cannot rule
out the possibility of an increased proportion in serum of
'big' IGFII from a different source, such as the liver. The
antiserum used against IGFII is known to cross-react with
partially processed pro-forms of IGFII, '10 kDa IGFII'
(Zumstein et al., 1985), excluding this from the possible
mediators of hypoglycaemia.
The effective supression of levels of both IGFs, and their
rapid recovery postoperatively are most likeiy a consequence
of the hypoglycaemia. The serum concentrations of the IGFs,
particularly IGFII, are sensitive to the concentration of both
insulin and in the case of IGFI, growth hormone, and it
seems likely that the low insulin levels induced by the hypo-
glycaemic state are responsible for the lowering of serum
IGFs (Phillips & Untermin, 1984). It is unlikely that the
tumour hypoglycaemia seen in this patient was due to
interaction of excess systemic insulin like growth factors with
the insulin receptor despite the presence of high levels of IGF
mRNA in the tumour.
Mr Desmond Oakland operated on the patient and Dr McGinty
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excellent technical assistance, and we are grateful for the continued
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